92248-94-7

Upstream product

• 140-29-4 phenylacetonitrile 
• 105-36-2 ethyl bromoacetate 
• 96-34-4 methyl chloroacetate 

Downstream Products

• 1014702-72-7 C₁₃H₁₅NO₃ 
• 1014701-47-3 {5-[2-(1-cyclopenanecarbonyl-3-phenyl-pyrrolidin-1-yl)-ethyl]-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl}-[3,5-dimethyl-1-(5-trifluoromethyl-pyridin-2-yl)-1H-pyrazol-4-yl]-methanone 
• 1014702-79-4 C₃₅H₄₃F₃N₆O₃ 
• 1014702-45-4 (5-{2-[1-(3,3-difluoro-cyclobutanecarbonyl)-3-phenyl-pyrrolidin-3-yl]-ethyl}-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-(3,5-dimethyl-1-pyrimidin-5-yl-1H-pyrazol-4-yl)-methanone 
• 1014701-42-8 5-(5-{2-[1-(3,3-difluoro-cyclobutanecarbonyl)-3-phenyl-pyrrolidin-3-yl]-ethyl}-hexahydro-pyrrolo[3,4-c]pyrrole-2-carbonyl)-4,6-dimethyl-pyridine-2-carbonitrile 
• 1014703-06-0 C₃₃H₄₃N₇O₃ 
• 1014702-77-2 C₃₂H₄₁N₅O₃ 
• 1014703-42-4 C₂₈H₃₅N₇O 
• 1014702-73-8 C₃₀H₄₁N₅O₃ 
• 1014701-37-1 1-(3-{2-[5-(4,6-dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-3-phenyl-pyrrolidin-1-yl)-ethanone 
• 1014702-75-0 C₃₀H₄₁N₃O₂ 
• 1014702-76-1 C₂₃H₃₅N₃O₂ 
• 616888-34-7 C₁₇H₂₃NO₃ 
• 22812-68-6 2-phenyl-propane-1,2,3-tricarboxylic acid trimethyl ester 

Relevant academic research and scientific papers

OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS

Chemokine receptor antagonists, in particular, 3,7-diazabicyclo [3.3.0] octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula (I).

4-Arylcyclohexylamines

The invention relates to novel 4-hydroxymethyl(acyloxymethyl and methyl)-4-arylcyclohexylamines embraced by the formula SPC1 Wherein Ar is an aromatic ring selected from the group consisting of phenyl and naphthyl, each of which has from zero through three substituents independently selected from the group consisting of fluorine, chlorine, bromine, lower alkyl of one through three carbon atoms, lower alkoxy of one through three carbon atoms, and lower alkylthio of one through three carbon atoms; Z is selected from the group consisting of hydrogen, hydroxy and lower acyloxy of one through four carbon atoms; ? is a generic expression denoting cis and trans stereoconfiguration and mixtures thereof, with the proviso that when the stereoconfiguration of the linkage connecting the cyclohexane ring and CH2 Z is cis to the amino group, the linkage connecting the cyclohexane and Ar rings is trans, and vice versa; R1 is selected from the group consisting of hydrogen and lower alkyl of one through three carbon atoms; R2 is selected from the group consisting of hydrogen, lower alkyl of one through three carbon atoms, EQU1 WHEREIN N IS 2 THROUGH 5 AND Ar has the same meaning as above; R1 and R2 taken together with --N is a saturated heterocyclic amino radical selected from the group consisting of unsubstituted and substituted pyrrolidino, piperidino, hexamethylenimino, morpholino and piperazino; and pharmacologically acceptable acid addition salts thereof. It also relates to intermediates and processes for the preparation of the aforesaid novel compounds (I) and novel derivatives thereof. The administration to humans and animals of the novel compounds (I) depresses their central nervous systems and lowers their blood pressures.